Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1250 45th St #320, Emeryville, CA 94608, USA
- Website
- topaz.bio
- Founded
- 2022
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Resvita Bio Inc. | Emeryville, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vulcan Biologics Inc. | — | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Osel, Inc. | Mountain View, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Siolta Therapeutics Inc. | San Carlos, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Topaz Biosciences, Inc. is a for-profit, woman-owned small business located in Emeryville, California, that specializes in developing novel microbiome-targeted therapeutic solutions using advanced metagenomic platforms. The company focuses on discovering and engineering endolysins, which are phage-encoded enzymes capable of precisely targeting and eliminating specific bacterial species without damaging beneficial bacteria. Registered in SAM.gov since July 2022, Topaz Biosciences has positioned itself as an innovative biotechnology firm working on highly specialized antimicrobial research and development.
The company has received multiple federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, focusing on developing targeted endolysins for treating specific bacterial conditions. These grants have supported research into novel endolysins targeting Gardnerella vaginalis to treat bacterial vaginosis and Cutibacterium acnes to treat acne vulgaris. The most recent awards, ranging from $300,000 to multi-year project grants, demonstrate the company's commitment to developing alternative antimicrobial treatments that can overcome limitations of traditional antibiotics. Specifically, Topaz Biosciences leverages its proprietary metagenomic platform to discover, engineer, and optimize endolysins with enhanced properties such as improved activity, thermostability, and pH tolerance. Their research aims to create high-specificity microbiome modulators that can selectively eliminate problematic bacteria while preserving beneficial microorganisms, potentially revolutionizing treatment approaches for conditions like bacterial vaginosis and acne.
Quick answers
Is Topaz Biosciences, Inc. registered in SAM.gov?
Yes. Topaz Biosciences, Inc.'s SAM.gov registration is active through June 27, 2027.
What is Topaz Biosciences, Inc.'s most recent federal award?
Topaz Biosciences, Inc.'s most recent federal grant award is Metagenomic discovery and optimization of novel endolysins targeting gardnerella vaginalis to treat bacterial vaginosis (R43AI186717), from National Institute of Allergy and Infectious Diseases (NIH), on July 8, 2024.
On GovTribe
See Topaz Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors